All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The European Medicines Agency (EMA) has granted CellProtect orphan drug designation for the treatment of Multiple Myeloma (MM). CellProtect technology is owned by CellProtect Nordic Pharmaceuticals AB (CPNP), and is, in essence, a process by which a patient's own natural killer (NK) cells are removed, activated, and expanded in-vitro. The activated cells, with enhanced immunocompetence, are then transferred back into the patient, enabling more effective killing of tumor cells.
This therapy is being tested in phase I/II clinical trials with MM patients that are being carried out at the Karolinska University Hospital in Sweden, as a supplementary treatment to Autologous Stem Cell Transplant (ASCT). To date, initial results from these trials have been promising, showing a good safety profile and effective outcomes, with the full results due to be published in 2018. This will be welcome news for MM patients who will be hoping to see effective cell therapies move closer to the clinic.
Subscribe to get the best content related to multiple myeloma delivered to your inbox